OpenLegislation

The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2021 in England

S.R. 2021/221 · Made 28 July 2021

Original text. legislation.gov.uk does not revise statutory instruments, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Dangerous Drugs

Made 28th July 2021

Coming into operation 18th August 2021

The Department of Healthf1 makes the following Regulations in exercise of the powers conferred by sections 7, 10 and 31 of the Misuse of Drugs Act 1971f2 as adapted by sections 7(9), 31(4) and 38 of that Act and now vested in itf3 and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act.

Annotations to the whole text

Footnotes

f1

Formerly the Department of Health, Social Services and Public Safety; see 2016 c. 5 (N.I.), s. 1(5)

f2

1971 c. 38 as amended by section 151 of, and Schedule 17 to, the Police Reform and Social Responsibility Act 2011 c.13

f3

S.R. & O. (N. I.) 1973 No. 504, Article 5(a) and S.I. 1999/283 (N.I. 1), Article 3(6)

Contents

  1. 1Citation, commencement and interpretation
  2. 2Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
  3. Signature
  4. Explanatory note

1Citation, commencement and interpretation

(1)

These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2021 and shall come into operation on 18th August 2021.

(2)

The Interpretation Act (Northern Ireland) 1954f1 shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.

2Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002

(1)

The following amendments are made to Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002f1 (which specifies controlled drugs that are subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27 of those Regulations).

(2)

In paragraph 1(a)—

(a)

after “Etryptamine” insert “Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;

(b)

after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H -[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;

(c)

after “Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”.

Signature

Sealed with the Official Seal of the Department of Health on 28th July 2021

(L.S.)

Cathy Harrison

A senior officer of the Department of Health

Explanatory note

(This note is not part of the Regulations)

These Regulations amend the Misuse of Drugs Regulations (Northern Ireland) 2002 (S.R. 2002 No. 1) (“the Regulations”).

Regulation 2 adds three benzodiazepines, being the compounds known as flualprazolam, flunitrazolam and norfludiazepam, to Schedule 1 to the Regulations. The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls, requiring a licence from the Department of Health in order to access such drugs.